Loop Biotech

The breakup separates Aetna and Caremark from retail pharmacies amid federal and state scrutiny of vertically integrated health care companies.

The review marks a key regulatory step for a one-time gene therapy in a fatal neurodegenerative disease, though approval remains uncertain.

Sanders could use the PDUFA reauthorization and his committee perch to press for drug pricing and FDA reforms.

Historical midterm patterns and expectations that Democrats will prioritize other fights over drug pricing underpin the bullish read.

The setback casts doubt on the prospects of drugs designed to degrade the hard-to-target STAT6 protein for immune conditions.

The lawsuit raises questions about the safety profile of the company's flagship MASH drug as it ramps up commercially.

The change bars hospitals and other providers from using third parties to deliver remote monitoring services, a practice critics say inflates billing.

The oral obesity drug's performance widens Novo's early edge over Eli Lilly in the pill segment of the weight loss market.

The layoffs come as the company ends development of two rare disease drugs, adding to a run of pipeline setbacks.

The results offer doctors evidence on which non-statin cholesterol medicine to choose for patients who need more risk reduction.

The restrictions leave rare disease families and US investors facing uncertainty over a once-flooding pipeline of early-stage studies.

The startup claims its platform can reach known but undruggable cancer targets and design selective autoimmune treatments.

The draft rules would tighten oversight of India's large generic drug manufacturing sector, a major source of global medicine supply.

Widespread chatbot use by clinicians is raising new questions about patient data privacy and HIPAA compliance.

The startup is developing a medicine for myeloproliferative neoplasms that an investor says could reach broader patient groups than approved drugs.

Republican losses leave RFK Jr.'s MAHA movement with an uncertain path while single-payer advocates see renewed momentum.

The company is among several developers whose Alzheimer's programs face heightened investor skepticism over clinical prospects.

The submission would make Compass a leading contender in the race to bring psychedelic-assisted therapy to the regulated market.

Executives expressed conviction in the coming IgA nephropathy launch, which Wall Street sees as important to Vertex's future.

The deal reflects continued demand for local clinical supply and logistics capacity in China's biopharma market.

Lawmakers must address ACA subsidies and Medicaid funding and confirm HHS nominees in an unusual post-election session.

Regulatory agreement on the pivotal design clears a path toward late-stage testing in the inherited retinal condition.

Rising uptake of the approved sickle cell gene therapy is being tracked as a bellwether for the commercial cell and gene therapy market.

Korean and Chinese cell therapy developers are using the ASH meeting to showcase data in multiple myeloma and other blood cancers.

The call offers a read on BioNTech's oncology pipeline and its transition beyond COVID vaccines.

The letter adds pressure on regulators weighing the Duchenne muscular dystrophy cell therapy amid a contested review.

The clearance advances late-stage development of the company's imaging agent used to detect disease in PET/CT scans.

Newly approved therapies for rare immune conditions face reimbursement and access challenges despite expanded treatment choices.

The Li Ka-shing-backed biotech is gaining international notice for its oncology pipeline.

The decisive defeat preserves the state's recreational cannabis industry and its tax revenue.

The provider is repositioning services around preventive and longevity-focused care in Asian markets.